baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Denali Therapeutics Inc/ US24823R1059 /

2024-07-29 10:00:00 PM	Chg. +0.2800	Volume	Bid1:50:00 AM	Ask1:50:00 AM	High	Low
24.3800USD	+1.16%	975,040 Turnover: 18.13 mill.	19.0000Bid Size: 200	25.9600Ask Size: 200	25.1000	23.8650

GlobeNewswire 06-13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

GlobeNewswire 06-03 Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome T...

GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 05-01 Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343...

GlobeNewswire 04-18 BioHive Announces BioHive Live

GlobeNewswire 04-01 Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Med...

GlobeNewswire 02-27 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...

GlobeNewswire 02-27 Denali Therapeutics Announces $500 million Private Placement Equity Financing

GlobeNewswire 02-07 Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzym...

GlobeNewswire 02-01 Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossin...

GlobeNewswire 01-08 Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its ...

GlobeNewswire 2023-11-27 Meet the Companies Named to Computerworld’s 2024 Best Places to Work in IT List

GlobeNewswire 2023-11-07 Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire 2023-11-07 US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spher...

GlobeNewswire 2023-09-08 Regeneron Announces Updates to Board of Directors

GlobeNewswire 2023-09-07 CENTOGENE Reports First Half 2023 Financial Results

GlobeNewswire 2023-08-30 Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (H...

GlobeNewswire 2022-03-15 Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krog...

GlobeNewswire 2022-03-09 Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Fronto...

GlobeNewswire 2022-02-28 Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlig...

GlobeNewswire 2022-02-10 Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Synd...

GlobeNewswire 2022-02-01 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...

GlobeNewswire 2022-01-23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...

GlobeNewswire 2022-01-13 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeu...

Denali Therapeutics Inc/ US24823R1059 /

If you wish to receive reply to your feedback, please provide your email address.